Valuation: Bioventix PLC

Market Cap 88.82M 118M 104M 95.32M 168M 11.21B 171M 1.15B 444M 5.5B 443M 433M 19.16B P/E 2026 *
12.7x
P/E 2027 * -
Enterprise Value 83.93M 111M 97.85M 90.07M 158M 10.6B 162M 1.08B 420M 5.2B 418M 409M 18.1B EV / Sales 2026 *
6.71x
EV / Sales 2027 * -
Free-Float
92.29%
Yield 2026 *
8.82%
Yield 2027 * -
1 day+3.03%
1 week-2.86%
Current month+3.03%
1 month+2.41%
3 months+4.62%
6 months-10.76%
Current year-10.76%
1 week 1,575
Extreme 1575
1,750
1 month 1,500
Extreme 1500
1,850
Current year 1,300
Extreme 1300
1,950
1 year 1,300
Extreme 1300
2,860
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 2003-12-22
Director of Finance/CFO 67 2020-06-30
Director TitleAgeSince
Director/Board Member 67 2010-11-24
Chairman 66 2004-10-31
Director/Board Member 67 2020-06-30
Date Insider Type Main position Quantity % Market Cap.
06-23Buy

Chief Financial Officer

534 0.0102%
04-27Buy

Chief Financial Officer

66 0.0013%
04-19Free

Chief Executive Officer

9,967 0.1908%
Change 5-day change 1-year change 3-year change Capi.($)
+3.03%-2.86%-43.71%-55.84% 114M
+3.08%+6.47%-0.25%+5.47% 47.18B
+0.12%+10.45%+408.29%+600.97% 39.82B
+5.17%+9.47%+24.96%-9.60% 32.25B
+2.02%+4.91%+18.59%+63.06% 31.68B
+0.69%+1.04%+14.23%+30.86% 24.59B
+0.40%+12.51% - - 16.57B
+2.64%+6.00%+69.30%+126.33% 15.12B
-0.15%+2.15%+12.64%+17.71% 13.69B
-0.13%+3.49%+98.27%+93.01% 13.1B
Average +1.69%+5.29%+66.93%+96.89% 23.41B
Weighted average by Cap. +1.88%+6.62%+94.20%+137.89%

Financials

2026 *2027 *
Net sales 12.5M 16.6M 14.57M 13.41M 23.57M 1.58B 24.05M 161M 62.51M 775M 62.32M 60.98M 2.7B -
Net income 7.11M 9.44M 8.29M 7.63M 13.41M 898M 13.69M 91.8M 35.57M 441M 35.46M 34.69M 1.53B -
Net Debt -4.89M -6.5M -5.71M -5.25M -9.23M -618M -9.42M -63.17M -24.47M -303M -24.4M -23.87M -1.06B -
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
26-07-01 GBX 1,700.00 +3.03% 2,435
26-06-30 GBX 1,650.00 -1.49% 2,755
26-06-29 GBX 1,675.00 0.00% 6,677
26-06-26 GBX 1,675.00 0.00% 1,002
26-06-25 GBX 1,675.00 -4.29% 4,191
Trader
Investor
Global
-
Quality
ESG MSCI
CCC

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BVXP Stock